{"nctId":"NCT00528840","briefTitle":"Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease","startDateStruct":{"date":"2007-10","type":"ACTUAL"},"conditions":["Advanced Dupuytren's Disease"],"count":201,"armGroups":[{"label":"AA4500 0.58 mg","type":"EXPERIMENTAL","interventionNames":["Biological: collagenase clostridium histolyticum"]}],"interventions":[{"name":"collagenase clostridium histolyticum","otherNames":["XIAFLEX®","AA4500"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with a diagnosis of advanced Dupuytren's disease, with a fixed flexion deformity of at least one finger, other than the thumb, that had a contracture at least 20°, but not greater than 100° for MP (80° for PIP) joints, caused by a palpable cord.\n* Had a positive \"table top test,\" defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top.\n* Were naïve to AA4500 treatment or had received one or two injections of AA4500 for the treatment of advanced Dupuytren's disease in Auxilium Studies AUX-CC-851, AUX-CC-853, or AUX-CC-855.\n* Were judged to be in good health.\n\nExclusion Criteria:\n\n* Had a chronic muscular, neurological, or neuromuscular disorder that affected the hands.\n* Had received treatment for advanced Dupuytren's disease within 90 days of enrollment on the joint selected for the initial injection of AA4500, including surgery (fasciectomy or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil and/or interferon.\n* Had a known recent history of stroke, bleeding, a disease process that affected the hands, or other medical condition, which in the investigator's opinion, would make the subject unsuitable for enrollment in the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Reduction in Contracture to 5° or Less","description":"The Primary Outcome Measure is the percentage of joints that were successfully treated where \"successfully treated\" was defined as reduction in contracture to within 0-5 degrees of normal within 30 days of injection","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Improvement After the Last Injection","description":"Clinical Improvement is defined as \\>=50% percent reduction from baseline in degree of contracture within 30 days after injection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Reduction From Baseline Contracture After the Last Injection","description":"Percent change in degree of contracture measured as 100\\*(baseline contracture -last available post-injection contracture)/baseline contracture)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.8","spread":"40.91"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Range of Motion After the Last Injection","description":"Change in degree of range of motion measured as last available post-injection range of motion - baseline range of motion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.3","spread":"20.15"}]}]}]},{"type":"SECONDARY","title":"Time to Reach Clinical Success","description":"Clinical success is defined as reduction in contracture to within 0-5 degrees of normal within 30 days of injection, displayed in post-injection timepoint categories.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Success After the First Injection","description":"Clinical Success is defined as reduction in contracture to within 0-5 degrees of normal within 30 days of injection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Improvement After the First Injection","description":"Clinical Improvement is defined as \\>=50% reduction from baseline in the degree of contracture within 30 days after the first injection","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Reduction From Baseline Contracture After the First Injection","description":"Percent change in degree of contracture is measured as 100\\* (baseline contracture- last available post-injection contracture)/baseline contracture.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.4","spread":"39.38"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Range of Motion After the First Injection","description":"Change in degree of range of motion measured as last available post-injection range of motion-baseline range of motion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.3","spread":"19.52"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":201},"commonTop":["Oedema peripheral","Injection site pain","Injection site haemorrhage","Contusion","Injection site swelling"]}}}